Eckert & Ziegler Strahlen und Medizintechnik AG
XHAM:EUZ
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| DE |
|
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
|
961.1m EUR |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
202.2B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
178.4B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
148B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
124.9B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
113.5B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.8B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
52.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.3B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
50.3B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
38.3B USD |
Loading...
|
Market Distribution
| Min | -5 776.5% |
| 30th Percentile | 29.1% |
| Median | 44.6% |
| 70th Percentile | 60.9% |
| Max | 184.7% |
Other Profitability Ratios
Eckert & Ziegler Strahlen und Medizintechnik AG
Glance View
Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Eckert & Ziegler Strahlen und Medizintechnik AG is 47.2%, which is below its 3-year median of 47.6%.
Over the last 3 years, Eckert & Ziegler Strahlen und Medizintechnik AG’s Gross Margin has decreased from 49.7% to 47.2%. During this period, it reached a low of 46.3% on Sep 30, 2023 and a high of 49.7% on Sep 30, 2022.
